Compare Jabil Inc (JBL) vs Repligen Corporation Common Stock (RGEN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Jabil Inc vs Repligen Corporation Common Stock — how do they compare? Jabil Inc trades at $288 (market cap $33.31B), while Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B). The key difference: Jabil Inc is far larger — about 3× Repligen Corporation Common Stock's market cap, and Jabil Inc pays a 0.1% dividend while Repligen Corporation Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Jabil Inc for 24 Days and Repligen Corporation Common Stock for 0 Days on average.
| JBL | RGEN | |
|---|---|---|
Market Cap | $33.31B | $11.14B |
Volume | 1,264,382 | 1,259,263 |
Sector | Technology | Health |
52-Week High | $385.50 | $194.57 |
52-Week Low | $192.49 | $102.87 |
Typical Hold Time | 24 Days | 0 Days |
Enterprise Value | $35.59B | $11.02B |
Dividend Yield | 0.1% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JBL trades at $317.86, up 1.87% with strong technical momentum and bullish moving averages. The company delivered three consecutive earnings beats, with Q2 2026 EPS of $4.40 beating expectations of $4.07. Revenue growth is accelerating, with fiscal 2027 guidance projecting 24% growth driven by AI infrastructure demand. Analyst consensus remains strongly bullish with a $434.75 price target representing 37% upside potential.
The outlook remains positive with AI-driven growth catalysts and strong institutional support, though risks include execution challenges in scaling operations and market volatility despite strong fundamentals. Current valuation at 32.6 P/E appears reasonable given the growth trajectory, while the 74.11% ROE demonstrates exceptional capital efficiency.
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Jabil Inc
Jabil is a global manufacturing solutions provider for industries including healthcare, automotive, and cloud. It offers comprehensive design, engineering, and supply chain management for complex electronic products.
Read more on JBL →About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →
